U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT06842407) titled 'Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)' on Feb. 14.
Brief Summary: The first objective of the project consists in the preclinical validation of new possible molecular targets associated with intratumoral T regulatory cells. The second objective consists in the selection of monoclonal antibodies with therapeutic potential, specific for the selected targets.
Study Start Date: April 01, 2023
Study Type: OBSERVATIONAL
Condition:
Healthy Donors
Recruitment Status: RECRUITING
Sponsor: Checkmab S.r.l.
Published by HT Digital Content Services with permission from Health Daily Digest....